BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jäntti MH, Mandrika I, Kukkonen JP. Human orexin/hypocretin receptors form constitutive homo- and heteromeric complexes with each other and with human CB1 cannabinoid receptors. Biochem Biophys Res Commun 2014;445:486-90. [PMID: 24530395 DOI: 10.1016/j.bbrc.2014.02.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Davies J, Chen J, Pink R, Carter D, Saunders N, Sotiriadis G, Bai B, Pan Y, Howlett D, Payne A, Randeva H, Karteris E. Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103. Sci Rep 2015;5:12584. [PMID: 26223541 DOI: 10.1038/srep12584] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
2 Flores Á, Julià-Hernández M, Maldonado R, Berrendero F. Involvement of the orexin/hypocretin system in the pharmacological effects induced by Δ(9) -tetrahydrocannabinol. Br J Pharmacol 2016;173:1381-92. [PMID: 26799708 DOI: 10.1111/bph.13440] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
3 Dale NC, Hoyer D, Jacobson LH, Pfleger KDG, Johnstone EKM. Orexin Signaling: A Complex, Multifaceted Process. Front Cell Neurosci 2022;16:812359. [DOI: 10.3389/fncel.2022.812359] [Reference Citation Analysis]
4 Fartootzadeh R, Alaei H, Reisi P. Mutual assistance of nucleus accumbens cannabinoid receptor-1 and orexin receptor-2 in response to nicotine: a single-unit study. Res Pharm Sci 2021;16:173-81. [PMID: 34084204 DOI: 10.4103/1735-5362.310524] [Reference Citation Analysis]
5 Thompson MD, Xhaard H, Sakurai T, Rainero I, Kukkonen JP. OX1 and OX2 orexin/hypocretin receptor pharmacogenetics. Front Neurosci 2014;8:57. [PMID: 24834023 DOI: 10.3389/fnins.2014.00057] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
6 Kim HJJ, Zagzoog A, Smolyakova AM, Ezeaka UC, Benko MJ, Holt T, Laprairie RB. In vivo Evidence for Brain Region-Specific Molecular Interactions Between Cannabinoid and Orexin Receptors. Front Neurosci 2021;15:790546. [PMID: 34992518 DOI: 10.3389/fnins.2021.790546] [Reference Citation Analysis]
7 Mestre L, Carrillo-Salinas FJ, Mecha M, Feliú A, Guaza C. Gut microbiota, cannabinoid system and neuroimmune interactions: New perspectives in multiple sclerosis. Biochem Pharmacol 2018;157:51-66. [PMID: 30171835 DOI: 10.1016/j.bcp.2018.08.037] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
8 Kukkonen JP. Allosteric interactions via the orthosteric ligand binding sites in a constitutive G-protein-coupled receptor homodimer. Pharmacol Res 2021;166:105116. [PMID: 32783977 DOI: 10.1016/j.phrs.2020.105116] [Reference Citation Analysis]
9 Li T, Xu W, Ouyang J, Lu X, Sherchan P, Lenahan C, Irio G, Zhang JH, Zhao J, Zhang Y, Tang J. Orexin A alleviates neuroinflammation via OXR2/CaMKKβ/AMPK signaling pathway after ICH in mice. J Neuroinflammation 2020;17:187. [PMID: 32539736 DOI: 10.1186/s12974-020-01841-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
10 Wang C, Wang Q, Ji B, Pan Y, Xu C, Cheng B, Bai B, Chen J. The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases. Front Mol Neurosci 2018;11:220. [PMID: 30002617 DOI: 10.3389/fnmol.2018.00220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 13.8] [Reference Citation Analysis]
11 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
12 Navarro G, Quiroz C, Moreno-Delgado D, Sierakowiak A, McDowell K, Moreno E, Rea W, Cai NS, Aguinaga D, Howell LA, Hausch F, Cortés A, Mallol J, Casadó V, Lluís C, Canela EI, Ferré S, McCormick PJ. Orexin-corticotropin-releasing factor receptor heteromers in the ventral tegmental area as targets for cocaine. J Neurosci 2015;35:6639-53. [PMID: 25926444 DOI: 10.1523/JNEUROSCI.4364-14.2015] [Cited by in Crossref: 45] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
13 Morales P, Reggio PH. An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. Cannabis Cannabinoid Res 2017;2:265-73. [PMID: 29098189 DOI: 10.1089/can.2017.0036] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 14.8] [Reference Citation Analysis]
14 Esteban PF, Garcia-ovejero D, Paniagua-torija B, Moreno-luna R, Arredondo LF, Zimmer A, Arevalo-martin A, Molina-holgado E. Revisiting CB1 cannabinoid receptor detection and the exploration of its interacting partners. Journal of Neuroscience Methods 2020;337:108680. [DOI: 10.1016/j.jneumeth.2020.108680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Oyagawa CRM, Grimsey NL. Cannabinoid receptor CB1 and CB2 interacting proteins: Techniques, progress and perspectives. Methods Cell Biol 2021;166:83-132. [PMID: 34752341 DOI: 10.1016/bs.mcb.2021.06.011] [Reference Citation Analysis]
16 Esmaeili M, Reisi Z, Ezzatpanah S, Haghparast A. Role of orexin-2 and CB1 receptors within the periaqueductal gray matter in lateral hypothalamic-induced antinociception in rats. Behavioural Pharmacology 2017;28:83-9. [DOI: 10.1097/fbp.0000000000000277] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
17 Ibrahim BM, Abdel-Rahman AA. A pivotal role for enhanced brainstem Orexin receptor 1 signaling in the central cannabinoid receptor 1-mediated pressor response in conscious rats. Brain Res 2015;1622:51-63. [PMID: 26096126 DOI: 10.1016/j.brainres.2015.06.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
18 Berrendero F, Flores Á, Robledo P. When orexins meet cannabinoids: Bidirectional functional interactions. Biochemical Pharmacology 2018;157:43-50. [DOI: 10.1016/j.bcp.2018.08.040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
19 Kukkonen JP. Orexin/Hypocretin Signaling. Curr Top Behav Neurosci 2017;33:17-50. [PMID: 27909990 DOI: 10.1007/7854_2016_49] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
20 Yaeger JD, Krupp KT, Gale JJ, Summers CH. Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity. Medicine in Drug Discovery 2020;8:100059. [DOI: 10.1016/j.medidd.2020.100059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Nasudi G, Salmani ME, Hosseinmardi N, Moradpour F, Lashkarbolouki T, Goudarzi I. Hippocampal orexin-1 and endocannabinoid-1 receptors underlie the kainate-induced occlusion in theta-burst long- term potentiation. Neuropeptides 2022. [DOI: 10.1016/j.npep.2022.102263] [Reference Citation Analysis]
22 Thompson MD, Sakurai T, Rainero I, Maj MC, Kukkonen JP. Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics. Pharmaceuticals (Basel) 2017;10:E79. [PMID: 28991183 DOI: 10.3390/ph10040079] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]